Sprache auswählen
EpCAM
EpCAM Molekülinformation
| Englischer Name | Epithelial cell adhesion molecule | Anzahl der inverkehr gebrachten Arzneimittel | 1 |
| Anzahl der klinischen Arzneimittel | 12 | Target-Alias | Epithelial Cell Adhesion Molecule，Tumor-Associated Calcium Signal Transducer 1，Major Gastrointestinal Tumor-Associated Protein GA733-2，Cell Surface Glycoprotein Trop-1，Epithelial Glycoprotein 314，TROP1，KSA，Membrane Component， Chromosome 4， Surface Marker (35kD Glycoprotein)，Antigen Identified By Monoclonal Antibody AUA1，Human Epithelial Glycoprotein-2，Epithelial Cell Surface Antigen，CD326 Antigen，HEGP314，HNPCC8，Ep-CAM，DIAR5，EGP-2，EGP40，KS1/4，MK-1，M1S2，ESA，Ly74，TACST-1，CO-17A，17-1A，EGP34，HEA125，MH99，MOC31，323/A3，Trophoblast Cell Surface Antigen 1，Adenocarcinoma-associated antigen，EGP314，GA733-2，M4S1，TACSTD1，Epithelial glycoprotein，EGP，KS 1/4 antigen，MIC18，CD326，EPCAM |
| Höchste Forschungs- und Entwicklungsphase | Approved | ||
| Englischer Name | Epithelial cell adhesion molecule |
| Target-Alias | Epithelial Cell Adhesion Molecule，Tumor-Associated Calcium Signal Transducer 1，Major Gastrointestinal Tumor-Associated Protein GA733-2，Cell Surface Glycoprotein Trop-1，Epithelial Glycoprotein 314，TROP1，KSA，Membrane Component， Chromosome 4， Surface Marker (35kD Glycoprotein)，Antigen Identified By Monoclonal Antibody AUA1，Human Epithelial Glycoprotein-2，Epithelial Cell Surface Antigen，CD326 Antigen，HEGP314，HNPCC8，Ep-CAM，DIAR5，EGP-2，EGP40，KS1/4，MK-1，M1S2，ESA，Ly74，TACST-1，CO-17A，17-1A，EGP34，HEA125，MH99，MOC31，323/A3，Trophoblast Cell Surface Antigen 1，Adenocarcinoma-associated antigen，EGP314，GA733-2，M4S1，TACSTD1，Epithelial glycoprotein，EGP，KS 1/4 antigen，MIC18，CD326，EPCAM |
| Anzahl der inverkehr gebrachten Arzneimittel | 1 |
| Anzahl der klinischen Arzneimittel | 12 |
| Höchste Forschungs- und Entwicklungsphase | Approved |
EpCAM Produktliste
- Attribut
Protein (12)Antibody (1)Cell (1)
- Produktbibliothek
Online (14)
- Spezies
Human (10)Mouse (1)Rhesus macaque (2)Rabbit (1)
- Etikett
Fc Tag (2)His Tag (4)His Tag & Avi Tag (2)Fc Tag & Avi Tag (1)Mouse IgG Fc Tag (1)Llama IgG Fc Tag (1)- (2)Tag Free (1)
- Marker
Unconjugated (8)Biotin-labeled (3)FITC Labeled (2)- (1)
In den Warenkorb legen
Gesamtmenge14
- 1
- 2
EpCAM Molekülhintergrund
EpCAM is also known as CO171A, EGP, EGP40,GA7332, KSA, M4S, MIC18, MK1, TROP1, hEGP2, and is a pan-epithelial differentiation antigen that is expressed on almost all carcinomas as 17-1A(mAb) antigen. Its constitutional function is being elucidated. It is intricately linked with the Cadherin-Catenin pathway and hence the fundamental WNT pathway responsible for intracellular signaling and polarity. The epithelial cell adhesion molecule (Ep-CAM) is known to express in most epithelial malignancies and was reported as a tumor marker or a candidate of molecular targeting therapy.
Ep-CAM cross signaling with N-cadherin involves Pi3K, resulting in the abrogation of the cadherin adhesion complexes in epithelial cells was reported. And Epithelial cell adhesion molecule (Ep-CAM) recently received increased attention as a prognostic factor in breast cancer.
EpCAM Molekülalias
EPCAM,TACSTD1,TROP1,CD326,DIAR5,EGP2,EGP314,EGP40,ESA,GA733-2,HNPCC8,HNPCC-8,KS1,4,KSA,M4S1,MIC18,MK1
Antikörperprojekt-Handelsplattform
| Projektname | Projektphase | Molekültyp | Molekülquelle | Krankheitsgebiet | Indikationen |
|---|---|---|---|---|---|
| EpCAM CAR-T -01 | IIT | CAR | Humanized Mouse | Solid Tumor | Gastric Cancer |
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Recombinant Anti-EpCAM and Anti-CD3Human-mouse Chimeric Bispecific Antibody for Injection (Wuhan Yzy Biopharma Co Ltd) | M-701 | Phase 3 Clinical | Wuhan Yzy Biopharma Co Ltd | Ascites; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Hydrothorax; Neoplasms; Ovarian Neoplasms; Pleural Effusion, Malignant; Solid tumours; Stomach Neoplasms | Details |
| Oportuzumab monatox | 4D5MOCB-ETA; VB4-845; VB-4847; B-4845; VB-845 | Phase 3 Clinical | Sesen Bio Inc, Viventia Biotech Inc | Carcinoma, Squamous Cell; Head and Neck Neoplasms; Mouth Neoplasms; Neoplasms, Squamous Cell; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms | Details |
| Anti-EPCAM CAR-T cell therapy (Sinobioway) | Phase 2 Clinical | Beijing Sinobioway Bioengineering Group Co Ltd | Liver Neoplasms; Stomach Neoplasms | Details | |
| DuoBody-EpCAMx4-1BB | BNT314/GEN1059; GEN-1059; GEN1059; BNT314 | Phase 2 Clinical | Biontech Se, Genmab A/S | Colorectal Neoplasms; Neoplasms; Solid tumours | Details |
| IMC-001(Immunofoco) | IMC001; IMC-001 | Phase 2 Clinical | Suzhou Immunofoco Biotechnology Co Ltd | Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Colorectal Neoplasms; Digestive System Neoplasms; Esophageal Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| BA-3182 | BA-3182 | Phase 1 Clinical | Bioatla | Adenocarcinoma; Solid tumours | Details |
| KK-2269 | KK-2269; KK2269 | Phase 1 Clinical | Kyowa Kirin Inc | Carcinoma, Non-Small-Cell Lung; Esophageal adenocarcinoma; Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| AM-928 | AM-928 | Phase 1 Clinical | AcadeMab Biomedical Inc | Colorectal Neoplasms; Head and Neck Neoplasms; Solid tumours; Thyroid Carcinoma, Anaplastic | Details |
| Varsetatug masetecan | CX-2051; Varseta-M | Phase 1 Clinical | Cytomx Therapeutics Inc, Immunogen Inc | Colorectal Neoplasms; Neoplasms; Solid tumours | Details |
| 99mTc-HE3-G3 | 99mTc-HE3-G3; 99-mTc-HE-3-G-3; 99m-Tc-HE-3-G-3; 99mTc-(HE)3-G3; 99mTc-(CO)3-(HE)3-Ec1; [99mTc]Tc(CO)3-(HE)3-Ec1 | Phase 1 Clinical | Tomsk National Research Medical Center Of The Russian Academy Of Sciences | Breast Neoplasms; Solid tumours | Details |
| A-337 | A-337 | Phase 1 Clinical | Evive Biotech Ltd | Neoplasms; Solid tumours | Details |
| PMC2129G12 | PMC2129G12 | Forevertech Biotechnologies Co Ltd | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Catumaxomab | LP000 | Approved | Neovii Biotech Gmbh, Trion Research | Removab, Korjuny | EU | Ascites | Lindis Biotech GmbH | 2009-04-20 | Ascites; Breast Neoplasms; Carcinoma; Carcinoma, Ovarian Epithelial; Colonic Neoplasms; Neoplasms; Ovarian Neoplasms; Stomach Neoplasms; Urinary Bladder Neoplasms | Details |
Produktrezensionen
A***O2025-07-30
0Menschen mögenI tested the FITC-EpCAM protein for binding to our anti-EpCAM CAR-T cells which were made by lentiviral transduction of human T cells . The protein stained the CAR-T cells but not the control T cells at both 10 ug/ml and 2 ug/ml. It's a good product.- K***n2023-05-03 1Menschen mögenOverall, we were very pleased with the entire process of buying and using the product—shipping was quick and the product was packaged and stored well. The protein was used in the development of a lateral-flow immunoassay (LFA) to detect for EpCAM. Combinations of anti-EpCAM antibodies were first screened using the product, from which we were able to successfully see strong binding on spot tests in duplicate for certain antibody combination pairs. These tests allowed us to confidently move forward with printing and assembling proper LFAs.
- J***a2021-09-17 0Menschen mögenWe received the product with a fairly fast speed, we used this product for antibody screening and ELISA. The product is robust and good quality.
- Molekülinformation
- Produktliste
- Inverkehr gebrachte Arzneimittelinformation
- Produktrezensionen
- Klinische Arzneimittelinformation
Teilen auf:
Online-Nachricht
Kontaktieren Sie uns
BettinastraBe 30, 60325 Frankfurt am Main